What is the 13F Pro Quality Score for EDIT?

13F Pro ranks Editas Medicine, Inc. (EDIT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EDIT's current score at https://13fpro.ai/research/EDIT (free sign-up required for the full ranking).

Where does 13F Pro source EDIT data?

All Editas Medicine, Inc. fundamentals and ownership data come directly from SEC EDGAR. Editas Medicine, Inc. files with the SEC under CIK 1650664. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EDIT in?

Editas Medicine, Inc. (EDIT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is EDIT research updated on 13F Pro?

EDIT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Editas Medicine, Inc.(EDIT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1650664 EDIT stock profile & AI dashboard →

13F Pro Quality Score

10.8/100

Rank #2,803 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

27.4/100

Profitability

2.4/100

Balance Sheet

0.8/100

Earnings Quality

30.0/100

Free Cash Flow

2.5/100

Institutional Flow

34.3/100

Revenue Scale

4.8/100

Dilution Risk

7.6/100

EDIT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Editas Medicine, Inc. (EDIT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EDIT at 10.8/100 on a 32-signal composite quality model, placing it at rank #2,803 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (0.8) and profitability (2.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Editas Medicine, Inc. reports quarterly revenue of $2.8M, net income of $-25.0M, free cash flow of $-23.2M. Top institutional holders of EDIT by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. EDIT trades on the Nasdaq exchange and files with the SEC under CIK 1650664. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EDIT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Editas Medicine, Inc. directly from SEC EDGAR. Editas Medicine, Inc.'s 13F Pro composite quality score has ranged between 3 and 28 since 2021, currently 10.8 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

Revenue

Q1 2026

$2.8M

Net Income

Q1 2026

$-25.0M

Free Cash Flow

Q1 2026

$-23.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+25.4% YoY

$40.5MFY 2025

FY20 $90.7MFY22 $19.7MFY24 $32.3MFY25 $40.5M

Net Income

+32.5% YoY

$-160.1MFY 2025

FY20 $-116.0MFY22 $-220.4MFY24 $-237.1MFY25 $-160.1M

Operating Income

+36.3% YoY

$-160.0MFY 2025

FY20 $-134.8MFY22 $-225.9MFY24 $-251.2MFY25 $-160.0M

EPS (Diluted)

+37.5% YoY

$-1.80FY 2025

FY20 $-1.98FY22 $-3.21FY24 $-2.88FY25 $-1.80

Total Assets

-45.4% YoY

$186.5MFY 2025

FY20 $572.6MFY22 $514.3MFY24 $341.6MFY25 $186.5M

Total Debt

-6.1% YoY

$58.6MFY 2025

FY20 —FY22 —FY24 $62.4MFY25 $58.6M

Op. Cash Flow

+21.4% YoY

$-165.2MFY 2025

FY20 $-179.8MFY22 $-177.3MFY24 $-210.3MFY25 $-165.2M

Metric	FY 2025	FY 2024	FY 2022	FY 2020	FY 2019	FY 2018
Revenue	$40.5M +25.4%	$32.3M +63.9%	$19.7M -78.3%	$90.7M +341.9%	$20.5M -35.7%	$31.9M
Net Income	$-160.1M +32.5%	$-237.1M -7.6%	$-220.4M -90.1%	$-116.0M +13.3%	$-133.7M -21.6%	$-110.0M
Operating Income	$-160.0M +36.3%	$-251.2M -11.2%	$-225.9M -67.6%	$-134.8M +4.3%	$-140.9M -23.9%	$-113.7M
EPS (Diluted)	$-1.80 +37.5%	$-2.88 +10.3%	$-3.21 -62.1%	$-1.98 +26.1%	$-2.68	—
Total Assets	$186.5M -45.4%	$341.6M -33.6%	$514.3M -10.2%	$572.6M +12.5%	$508.9M +21.1%	$420.4M
Total Debt	$58.6M -6.1%	$62.4M	—	—	—	—
Operating Cash Flow	$-165.2M +21.4%	$-210.3M -18.6%	$-177.3M +1.4%	$-179.8M -342.2%	$-40.7M +11.0%	$-45.7M

AI Insight: EDIT Financial Trends

Editas shows dramatic improvement in profitability with net loss shrinking from $-76M in Q1 2025 to $-6M in Q4 2025, though equity has collapsed 94% from $232M to $4M.

• Net loss improved significantly from $-76M in Q1 2025 to $-6M in Q4 2025 before widening to $-25M in Q1 2026.

• Operating cash flow improved from $-57M in Q2 2024 to $-23M in Q1 2026, showing reduced cash burn.

• Total equity collapsed 98% from $232M in Q2 2024 to $4M in Q1 2026.

• Revenue remains lumpy, ranging from $0M to $31M quarterly with no clear growth pattern.

⚠ Equity at critical $4M level suggests potential funding needs or dilutive financing risk ahead.

⚠ Net loss deteriorated from $-6M in Q4 2025 back to $-25M in Q1 2026, reversing recent progress.

AI Insight: EDIT Ratio Trends

Editas shows mixed progress with operating margin improving dramatically from -152.2% to -31.3%, but ROA deteriorating and debt-to-equity ratio spiking to 12.40.

• Operating margin improved significantly from -152.2% in Q4 2024 to -31.3% in Q4 2025.

• Net profit margin recovered from -148.3% in Q4 2024 to -22.7% in Q4 2025.

• ROA improved from -53.2% in Q4 2024 to -12.0% in Q4 2025.

• ROIC strengthened from -94.8% in Q4 2024 to -36.1% in Q4 2025.

⚠ Debt-to-equity ratio spiked from 2.15 in Q4 2025 to 12.40 in Q1 2026.

⚠ ROA deteriorated from -12.0% in Q4 2025 to -66.9% in Q1 2026.

Get alerted when EDIT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Editas Medicine, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EDIT

BlackRock, Inc.
$22.9M9,263,312 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.4M4,204,369 sh
RENAISSANCE TECHNOLOGIES LLC
$9.8M3,972,160 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$7.8M3,148,570 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.7M2,311,789 sh
STATE STREET CORP
$5.1M2,076,122 sh
Nuveen, LLC
$4.9M1,977,509 sh
D. E. Shaw & Co., Inc.
$4.8M1,943,893 sh
Opaleye Management Inc.
$4.8M1,926,997 sh
TWO SIGMA INVESTMENTS, LP
$3.8M1,549,063 sh

Fund	Value	Shares
BlackRock, Inc.	$22.9M	9,263,312
VANGUARD CAPITAL MANAGEMENT LLC	$10.4M	4,204,369
RENAISSANCE TECHNOLOGIES LLC	$9.8M	3,972,160
VANGUARD PORTFOLIO MANAGEMENT LLC	$7.8M	3,148,570
GEODE CAPITAL MANAGEMENT, LLC	$5.7M	2,311,789
STATE STREET CORP	$5.1M	2,076,122
Nuveen, LLC	$4.9M	1,977,509
D. E. Shaw & Co., Inc.	$4.8M	1,943,893
Opaleye Management Inc.	$4.8M	1,926,997
TWO SIGMA INVESTMENTS, LP	$3.8M	1,549,063

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EDIT on your watchlist

Track score changes the day Editas Medicine, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EDIT a good stock to buy?

13F Pro's AI-powered analysis of Editas Medicine, Inc. (EDIT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EDIT are available on the EDIT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own EDIT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EDIT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Editas Medicine, Inc.'s investment landscape.